BETHESDA, MarylandMerck & Co. will use a worldwide research network
organized and funded by the National Institute of Allergy and Infectious
Diseases (NIAID) to test promising HIV vaccines it develops.
The agreement will
enable Merck to evaluate its vaccines in a collaborative effort with the
international HIV Vaccine Trials Network (HVTN), which consists of centers at
12 US academic sites and 13 institutions in Africa, Asia, South America, and